Cited by 1,149Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismTrace Elements in Health

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., Marsden, C. D.·1989·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.1989.tb07264.x

Open this paper in CoChat — free account

Abstract

Levels of iron, copper, zinc, manganese, and lead were measured by inductively coupled plasma spectroscopy in parkinsonian and age-matched control brain tissue. There was 31-35% increase in the total iron content of the parkinsonian substantia nigra when compared to control tissue. In contrast, in the globus pallidus total iron levels were decreased by 29% in Parkinson's disease. There was no change in the total iron levels in any other region of the parkinsonian brain. Total copper levels were reduced by 34-45% in the substantia nigra in Parkinson's disease; no difference was found in the other brain areas examined. Zinc levels were increased in substantia nigra in Parkinson's disease by 50-54%, and the zinc content of the caudate nucleus and lateral putamen was also raised by 18-35%. Levels of manganese and lead were unchanged in all areas of the parkinsonian brain studied when compared to control brains, except for a small decrease (20%) in manganese content of the medial putamen. Increased levels of total iron in the substantia nigra may cause the excessive formation of toxic oxygen radicals, leading to dopamine cell death.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.1989.tb07264.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Self-citation
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,377
FERRITIN: STRUCTURE, GENE REGULATION, AND CELLULAR FUNCTION IN ANIMALS, PLANTS, AND MICROORGANISMS
Theil, E. C. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.001445 · Cited by 1,337
Increased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
Self-citation
Autoxidation versus Covalent Binding of Quinones as the Mechanism of Toxicity of Dopamine, 6-Hydroxydopamine, and Related Compounds toward C1300 Neuroblastoma Cells in Vitro
Graham, D. G., Tiffany, S. M., BELL, W. R., & Gutknecht, W. F. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13536-0 · Cited by 953
The importance of free radicals and catalytic metal ions in human diseases.
Halliwell, B., & Gutteridge, J. M. C. (1985) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(85)90001-9 · Cited by 941
Iron-Responsive Elements: Regulatory RNA Sequences That Control mRNA Levels and Translation
Casey, J. L., Hentze, M. W., Koeller, D. M., Caughman, S. W., Rouault, T. A., Klausner, R. D., & Harford, J. B. (1988) · Science · doi:10.1126/science.2452485 · Cited by 709
Brain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Woert, M. H. V., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 404

Show all 29 references

Research works printed but not linked: 4

Barbeau A., 1985, Uneven prevalence of Parkinson's disease in the province of Quebec, Can. J. Neurol. Sci., 12, 169
Barbeau A., 1986, Advances in Neurology, 299
Donaldson J., 1974, Advances in Neurology, 245
Youdim M. B. H., 1985, Handbook of Neurochemisiry, 731

Sorted by citations

Items 301–400 of 1,000

Common and Trace Metals in Alzheimer’s and Parkinson’s Diseases
Doroszkiewicz, J., Farhan, J. A., Mroczko, J., Winkel, I., Perkowski, M., & Mroczko, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115721 · Cited by 108
Metalloproteomics and metal toxicology of α-synuclein
Santner, A. A., & Uversky, V. N. (2010) · Metallomics · doi:10.1039/b926659c · Cited by 104
Parkinson’s disease: oxidative stress and therapeutic approaches
Surendran, S., & Rajasankar, S. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0245-1 · Cited by 106
Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers
Sengstock, G. J., Olanow, C. W., Menzies, R. A., Dunn, A. J., & Arendash, G. W. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490350109 · Cited by 105
A rat model of Parkinson's disease induced by Japanese encephalitis virus
Ogata, A., Tashiro, K., Nukuzuma, S., Nagashima, K., & Hall, W. W. (1997) · Journal of NeuroVirology · doi:10.3109/13550289709015803 · Cited by 105
Diffusion-MRI in neurodegenerative disorders
Goveas, J., O’Dwyer, L., Mascalchi, M., Cosottini, M., Diciotti, S., De Santis, S., Passamonti, L., Tessa, C., Toschi, N., & Giannelli, M. (2015) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2015.04.006 · Cited by 104
Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases
Xiang, Y., Song, X., & Long, D. (2024) · Archives of Toxicology · doi:10.1007/s00204-023-03660-8 · Cited by 116
Nitric Oxide Triggers the Toxicity due to Glutathione Depletion in Midbrain Cultures through 12-Lipoxygenase
Canals, S., Casarejos, M. J., de Bernardo, S., Rodríguez‐Martín, E., & Mena, M. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213174200 · Cited by 103
Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in MES23.5 cells
Zhang, S., Wang, J., Song, N., Xie, J., & Jiang, H. F. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.025 · Cited by 104
Structural and Morphological Characterization of Aggregated Species of α-Synuclein Induced by Docosahexaenoic Acid
Franceschi, G. D., Frare, E., Pivato, M., Relini, A., Penco, A., Greggio, E., Bubacco, L., Fontana, A., & de Laureto, P. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202937 · Cited by 109
Influence of neuromelanin on oxidative pathways within the human substantia nigra
Double, K. L., Ben-Shachar, D., Youdim, M. B. H., Zecca, L., Riederer, P., & Gerlach, M. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00218-0 · Cited by 102
Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients
Du, G., Lewis, M. M., Sica, C. T., He, L., Connor, J. R., Kong, L., Mailman, R. B., & Huang, X. (2018) · Movement Disorders · doi:10.1002/mds.27318 · Cited by 102
Iron in parkinsonian and control substantia nigra—A mössbauer spectroscopy study
Gałązka-Friedman, J., Bauminger, E. R., Friedman, A., Barcikowska, M., Hechel, D., & Nowik, I. (1996) · Movement Disorders · doi:10.1002/mds.870110104 · Cited by 102
Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?
Prigent, A., Agid, Y., & Hirsch, É. C. (1994) · Brain Research · doi:10.1016/0006-8993(94)90511-8 · Cited by 102
Self-citation
Redox active metals in neurodegenerative diseases
Acevedo, K. M., Masaldan, S., Opazo, C., & Bush, A. I. (2019) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-019-01731-9 · Cited by 102
Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease
Lan, J., & Jiang, D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291883 · Cited by 100
Iron in neurodegenerative disorders
Berg, D., Becker, G., Riederer, P. F., & Rieß, O. (2002) · Neurotoxicity Research · doi:10.1080/1029842021000045444 · Cited by 98
Impaired iron homeostasis in Parkinson’s disease
Double, K. L., Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_3 · Cited by 101
Magnetic Resonance Imaging in Parkinsonism
Olanow, C. W. (1992) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30218-4 · Cited by 99
Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease
Scheider, W. L., Hershey, L. A., Vena, J. E., Holmlund, T., Marshall, J. R., & Freudenheim, J. L. (1997) · Movement Disorders · doi:10.1002/mds.870120209 · Cited by 98
The roles of non-coding RNAs in Parkinson’s disease
Majidinia, M., Mihanfar, A., Rahbarghazi‬, R., Nourazarian, A., Bağca, B. G., & Avcı, Ç. B. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4054-3 · Cited by 96
Impairment of Interrelated Iron- and Copper Homeostatic Mechanisms in Brain Contributes to the Pathogenesis of Neurodegenerative Disorders
Skjørringe, T., Møller, L. B., & Moos, T. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00169 · Cited by 104
Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease
Abe, T., Isobe, C., Murata, T., Sato, C., & Tohgi, H. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01259-4 · Cited by 98
Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity
Lee, D. W., Rajagopalan, S., Siddiq, A., Gwiazda, R. H., Yang, L., Beal, M. F., Ratan, R. R., & Andersen, J. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000638 · Cited by 97
Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease
Oh, S., Chang, M., Song, J., Rhee, Y., Joe, E.-H., Lee, H., Yi, S., & Lee, S. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404610 · Cited by 104
Role of iron and iron chelation in dopaminergic-induced neurodegeneration: Implication for Parkinson's disease
Ben‐Shachar, D., Eshel, G., Riederer, P. F., & Youdim, M. B. H. (1992) · Annals of Neurology · doi:10.1002/ana.410320718 · Cited by 95
Analysis of Trace Elements in Human Brain: Its Aim, Methods, and Concentration Levels
Grochowski, C., Blicharska, E., Krukow, P., Jonak, K., Maciejewski, M., Szczepanek, D., Jonak, K. E., Flieger, J., & Maciejewski, R. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00115 · Cited by 94
Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor α or 1-methyl-4-phenylpyridinium treatment
Fillebeen, C., Ruchoux, M., Mitchell, V. A., Vincent, S., Benaı̈ssa, M., & Pierce, A. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(01)00216-9 · Cited by 93
Dietary Iron Intake and Risk of Parkinson's Disease
Logroscino, G., Gao, X., Chen, H., Wing, A., & Ascherio, A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn273 · Cited by 93
Molecular changes in the postmortem parkinsonian brain
Toulorge, D., Schapira, A. H. V., & Hajj, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13696 · Cited by 95
Magnetic resonance imaging of the substantia nigra in Parkinson's disease
Lehéricy, S., Sharman, M. A., dos Santos, C. L., Paquin, R., & Galléa, C. (2012) · Movement Disorders · doi:10.1002/mds.25015 · Cited by 97
Perspectives on MAO-B in Aging and Neurological Disease: Where Do We Go From Here?
Kumar, M. J., & Andersen, J. K. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:1:077 · Cited by 92
Multi-atlas tool for automated segmentation of brain gray matter nuclei and quantification of their magnetic susceptibility
Li, X., Chen, L., Kutten, K. S., Ceritoglu, C., Li, Y., Kang, N., Hsu, J. T., Qiao, Y., Wei, H., Liu, C., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.02.016 · Cited by 96
Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain
Bilska‐Wilkosz, A., Dubiel, M., ewicz, M. S. O.-J., Lorenc‐Koci, E., & Włodek, L. B. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.04.002 · Cited by 91
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication
Buhmann, C., Arlt, S., Kontush, A., Möller-Bertram, T., Sperber, S., Oechsner, M., Stuerenburg, H. J., & Beisiegel†, U. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.003 · Cited by 91
Hydroxypyridinone Journey into Metal Chelation
Cilibrizzi, A., Abbate, V., Chen, Y., Ma, Y., Zhou, T., & Hider, R. C. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00254 · Cited by 90
Iron induces degeneration of nigrostriatal neurons
Sengstock, G. J., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90118-h · Cited by 90
Magnetic Resonance Imaging Evidence of Decreased Putamenal Iron Content in Idiopathic Parkinson's Disease
Ryvlin, P., Broussolle, E., Piollet, H., Viallet, F., Khalfallah, Y., & Chazot, G. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540300057013 · Cited by 90
Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics
Savitt, D., & Jankovic, J. J. (2019) · Drugs · doi:10.1007/s40265-019-01104-1 · Cited by 93
Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice
Asanuma, M., Hirata, H., & Cadet, J. L. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00665-9 · Cited by 89
Caffeic Acid Phenethyl Ester Protects against the Dopaminergic Neuronal Loss Induced by 6-Hydroxydopamine in Rats
Barros Silva, R., Santos, N. A. G., Martins, N. M., Ferreira, D. A. S., Barbosa, F., Oliveira Souza, V. C., Kinoshita, Â., Baffa, O., Del-Bel, E., & Santos, A. C. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.041 · Cited by 88
Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping
Azuma, M., Hirai, T., Yamada, K., Yamashita, S., Ando, Y., Tateishi, M., Iryo, Y., Yoneda, T., Kitajima, M., Wang, Y., et al. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4645 · Cited by 88
Basal ganglia iron content in Parkinson's disease measured with magnetic resonance
Ye, F. Q., Allen, P. S., & Martin, W. R. W. (1996) · Movement Disorders · doi:10.1002/mds.870110305 · Cited by 88
Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease
Riederer, P. F., Dirr, A., Goetz, M. E., Sofic, E., Jellinger, K. A., & Youdimt, M. B. H. (1992) · Annals of Neurology · doi:10.1002/ana.410320717 · Cited by 88
Functional relevance of ceruloplasmin mutations in Parkinson's Disease
Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87
Prevention of 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons
Pong, K., Doctrow, S. R., & Baudry, M. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02841-9 · Cited by 87
Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences
Sergi, D., Renaud, J., Simola, N., & Martinoli, M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00302 · Cited by 87
The structure of neuromelanin and its iron binding site studied by infrared spectroscopy
Bridelli, M. G., Tampellini, D., & Zecca, L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01001-7 · Cited by 86
Parkinson's disease and age: The obvious but largely unexplored link
Abdullah, R., Basak, I., Patil, K. S., Alves, G. W., Larsen, J. P., & Møller, S. G. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.09.014 · Cited by 87
The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson’s disease
Al‐Hilaly, Y. K., Biasetti, L., Blakeman, B. J. F., Pollack, S. J., Zibaee, S., Abdul‐Sada, A. K., Thorpe, J. R., Xue, W., & Serpell, L. C. (2016) · Scientific Reports · doi:10.1038/srep39171 · Cited by 85
Nuclear factor‐kappa B (NF‐κB) in pathophysiology of Parkinson disease: Diverse patterns and mechanisms contributing to neurodegeneration
Dolatshahi, M., Hameghavandi, M. H. R., Sabahi, M., & Rostamkhani, S. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15242 · Cited by 87
Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths
Schenck, J. F. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00203-e · Cited by 85
Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress
Chung, E. S., Chung, Y. C., Bok, E., Baik, H. H., Park, E. S., Park, J., Yoon, S., & Jin, B. K. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.049 · Cited by 82
Die Parkinson-Krankheit
Berg, D., & Riederer, P. F. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4_8 · Cited by 83
In vitro aggregation assays for the characterization of α-synuclein prion-like properties
Narkiewicz, J., Giachin, G., & Legname, G. (2014) · Prion · doi:10.4161/pri.28125 · Cited by 86
Iron, Copper, and Zinc Distribution of the Cerebellum
Popescu, B. F. G., Robinson, C. A., Rajput, A. H., Rajput, A. H., Harder, S. L., & Nichol, H. K. (2009) · The Cerebellum · doi:10.1007/s12311-008-0091-3 · Cited by 83
Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease
Ahlskog, J. E. (2004) · Movement Disorders · doi:10.1002/mds.20362 · Cited by 83
Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells
Molina‐Holgado, F., Gaeta, A., Francis, P. T., Williams, R. J., & Hider, R. C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05332.x · Cited by 84
Impairment of emotional behavior and spatial learning in adult Wistar rats by ferrous sulfate
Maâroufi, K., Ammari, M., Jeljeli, M., Roy, V., Sakly, M., & Abdelmelek, H. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.10.019 · Cited by 83
Metal changes in CSF and peripheral compartments of parkinsonian patients
Bocca, B., Alimonti, A., Senofonte, O., Pino, A., Violante, N., Petrucci, F., Sancesario, G., & Forte, G. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.007 · Cited by 82
Natural melanin pigments and their interfaces with metal ions and oxides: emerging concepts and technologies
Mauro, E. D., Xu, R., Soliveri, G., & Santato, C. (2017) · MRS Communications · doi:10.1557/mrc.2017.33 · Cited by 82
Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease: The Emerging Role of VDAC
Risiglione, P., Zinghirino, F., Rosa, M. C. D., Magrì, A., & Messina, A. A. (2021) · Biomolecules · doi:10.3390/biom11050718 · Cited by 84
Generation of Reactive Oxygen Species by Mitochondrial Complex I: Implications in Neurodegeneration
Fato, R., Bergamini, C., Leoni, S., Strocchi, P., & Lenaz, G. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9747-0 · Cited by 81
New Progress on the Role of Glia in Iron Metabolism and Iron-Induced Degeneration of Dopamine Neurons in Parkinson’s Disease
Xu, H., Wang, Y., Song, N., Wang, J., Jiang, H. F., & Xie, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00455 · Cited by 82
Biochemistry of Parkinson's disease with special reference to the dopaminergic systems
Hirsch, É. C. (1994) · Molecular Neurobiology · doi:10.1007/bf02816113 · Cited by 80
Nitric Oxide, Iron and Neurodegeneration
Liu, C., Liang, M. C., & Soong, T. W. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00114 · Cited by 80
Oxidative stress and Parkinson's disease
Jenner, P. G. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83024-7 · Cited by 79
Self-citation
Different 8-Hydroxyquinolines Protect Models of TDP-43 Protein, α-Synuclein, and Polyglutamine Proteotoxicity through Distinct Mechanisms
Tardiff, D. F., Tucci, M. L., Caldwell, K. A., Caldwell, G. A., & Lindquist, S. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308668 · Cited by 78
Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
Hare, D. J., Adlard, P. A., Doble, P. A., & Finkelstein, D. I. (2013) · Metallomics · doi:10.1039/c2mt20164j · Cited by 78
Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis
Pyatigorskaya, N., Sanz-Morère, C. B., Gaurav, R., Biondetti, E., Valabrègue, R., Santin, M. D., Yahia‐Cherif, L., & Lehéricy, S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00366 · Cited by 78
Therapeutic Insights on Ferroptosis in Parkinson's disease
Thapa, K., Khan, H., Kanojia, N., Singh, T. G., Kaur, A., & Kaur, G. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175133 · Cited by 76
Zinc-induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3
Lin, A. M., Fan, S., Yang, D., Hsu, L. L., & Yang, J. C. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00105-9 · Cited by 78
The mechanism of neuroprotective action of natural compounds
Wąsik, A., & Antkiewicz‐Michaluk, L. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.03.018 · Cited by 79
Essential Cellular Regulatory Elements of Oxidative Stress in Early and Late Phases of Apoptosis in the Central Nervous System
Chong, Z. Z., Kang, J., & Maiese, K. (2004) · Antioxidants and Redox Signaling · doi:10.1089/152308604322899341 · Cited by 78
Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early‐stage Parkinson's disease
Reimão, S., Ferreira, S., Nunes, R. G., Lobo, P. P., Neutel, D., Abreu, D., Gonçalves, N., Campos, J., & Ferreira, J. J. (2015) · European Journal of Neurology · doi:10.1111/ene.12838 · Cited by 77
Iron-dependent functions of mitochondria—relation to neurodegeneration
Gille, G., & Reichmann, H. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0503-7 · Cited by 77
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
Studies on genomic DNA topology and stability in brain regions of Parkinson’s disease
Hegde, M. L., Gupta, V. B., Anitha, M., Harikrishna, T., Shankar, S. K., Muthane, U. B., Rao, K. S. J., & Rao, K. S. J. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.02.018 · Cited by 77
Magnetic susceptibility quantification for arbitrarily shaped objects in inhomogeneous fields
Li, L. (2001) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1276 · Cited by 76
Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism.
Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J. J., & Ogawa, N. (2004) · PubMed · doi:10.18926/amo/32105 · Cited by 76
Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson’s Disease
Shahrani, M. M. A., Heales, S., Hargreaves, I. P., & Orford, M. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110100 · Cited by 79
Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism
Tsai, C., Wu, R., Huang, Y.-W., Chen, L., Yip, P., & Jeng, J. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0403-9 · Cited by 76
Neuronal response in Alzheimer’s and Parkinson’s disease: the effect of toxic proteins on intracellular pathways
Majd, S., Power, J. H. T., & Grantham, H. J. M. (2015) · BMC Neuroscience · doi:10.1186/s12868-015-0211-1 · Cited by 79
Decreased circulating Zinc levels in Parkinson’s disease: a meta-analysis study
Du, K., Liu, M., Zhong, X., & Wei, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-04252-0 · Cited by 75
Oxidative damage and cerebral aging
LeBel, C. P., & Bondy, S. C. (1992) · Progress in Neurobiology · doi:10.1016/0301-0082(92)90043-e · Cited by 75
Dopamine-Dependent Iron Toxicity in Cells Derived from Rat Hypothalamus
Paris, I., Martinez-Alvarado, P., Cárdenas, S., Perez-Pastene, C., Graumann, R., Fuentes, P., Olea-Azar, C., Caviedes, P., & Segura-Aguilar, J. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0497144 · Cited by 74
Recent Advances on the Neuroprotective Potential of Antioxidants in Experimental Models of Parkinson’s Disease
Koppula, S., Kumar, H., More, S. V., Kim, B., Kim, I. S., & Choi, D. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130810608 · Cited by 76
Interaction Between α-Synuclein and Metal Ions, Still Looking for a Role in the Pathogenesis of Parkinson’s Disease
Bisaglia, M., Tessari, I., Mammi, S., & Bubacco, L. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8082-1 · Cited by 74
Systemic Vitamin D3 Attenuated Oxidative Injuries in the Locus Coeruleus of Rat Brain
CHEN, K., Lin, A. M.-Y., & Chiu, T. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07539.x · Cited by 74
Synaptic Zinc: An Emerging Player in Parkinson’s Disease
Sikora, J., & Ouagazzal, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094724 · Cited by 71
Parkinson’s Disease: The Mitochondria-Iron Link
Muñoz, Y., Carrasco, C. M., Campos, J., Aguirre, P., & Núñez, M. T. (2016) · Parkinson s Disease · doi:10.1155/2016/7049108 · Cited by 76
Oxidative Stress Partially Contributes to Iron-Induced Alpha-Synuclein Aggregation in SK-N-SH Cells
Li, W., Jiang, H. F., Song, N., & Xie, J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9187-x · Cited by 73
Copper Efflux from Murine Microvascular Cells Requires Expression of the Menkes Disease Cu-ATPase
Qian, Y., Tiffany‐Castiglioni, E., Welsh, J., & Harris, E. D. (1998) · Journal of Nutrition · doi:10.1093/jn/128.8.1276 · Cited by 72
Melatonin suppresses iron-induced neurodegeneration in rat brain
Lin, A. M.-Y., & Ho, L. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00169-6 · Cited by 72
Zinc, a neurotoxin to cultured neurons, contaminates cycad flour prepared by traditional guamanian methods
Duncan, M. W., Marini, A., Watters, R., Kopin, I. J., & Markey, S. P. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-04-01523.1992 · Cited by 72
Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs
Tosato, M., & Marco, V. D. (2019) · Biomolecules · doi:10.3390/biom9070269 · Cited by 71
Neuromelanin-sensitive MRI as a promising biomarker of catecholamine function
Trujillo, P., Aumann, M. A., & Claassen, D. O. (2023) · Brain · doi:10.1093/brain/awad300 · Cited by 79
Effect of mitochondrial complex I inhibition on Fe–S cluster protein activity
Mena, N. P., Bulteau, A., Salazar, J., Hirsch, É. C., & Núñez, M. T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.137 · Cited by 71
Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways
Anandhan, A., Rodríguez‐Rocha, H., Bohovych, I., Griggs, A. M., Zavala-Flores, L. M., Reyes‐Reyes, E. M., Seravalli, J., Stanciu, L., Lee, J., Rochet, J., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.018 · Cited by 73
The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals
Yoshioka, M., Tanaka, K.-I., Miyazaki, I., Fujita, N., Higashi, Y., Asanuma, M., & Ogawa, N. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00040-8 · Cited by 71

Authors: Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D.
Affiliations: King's College London (GB)
National Hospital for Neurology and Neurosurgery (GB)
Inserm (FR)
Corresponding author: Jenner, P.
ORCID: Dexter, D. T.
Jenner, P.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 1989-06
Volume: 52
Issue: 6
Pages: 1830-1836
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1111/j.1471-4159.1989.tb07264.x
OpenAlex: W1985613988
Cited by: 1,149
References: 29
Citations by year: 2026: 18 · 2025: 26 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 42 · 2020: 35 · 2019: 33 · 2018: 35 · 2017: 41 · 2016: 45 · 2015: 21 · 2014: 37 · 2013: 45 · 2012: 41
FWCI: 24.67
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 6335 d)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
Keywords: Parkinson's disease, substantia nigra, iron, copper, zinc, manganese, lead, globus pallidus, caudate nucleus, putamen, oxidative stress, neurodegeneration
MeSH terms: Aged, Aged, 80 and over, Brain, Female, Humans, Ions, Iron, Male, Metals, Parkinson Disease, Substantia Nigra, Tissue Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks